Concept explainers
(a)
To write:
The constitutive activation of Ras-like protein (RasD) by a mutation in the Ras protein. The way in which activation of Ras promote cancer. The type of mutation that reduces the Smad3 protein constitutively.
Introduction:
Constitutive activation is a phenomenon of the protein or signaling pathway modification. This modification is functional or involved in an upstream activating event absence. For instance, RasD is constitutively active as it does not bind the GTPase Activating Protein (GAP). Thus, it remains in the GTP-bound (active state) even when the cells are not triggered by growth factor to stimulate a receptor tyrosine kinase (RTK). Constitutively active Ras acts as cancer stimulating as the cells will flourish in the growth factors absence. Therefore, the standard regulatory mechanisms for cell proliferation are avoided.
(b)
To write:
The constitutive activation of (RasD) by a mutation in the Ras protein. The way in which activation of Ras promote cancer. The type of mutation that reduces the MAP kinase proteins constitutively.
Introduction:
Constitutive activation is a phenomenon of the protein or signaling pathway modification. This modification is functional or involved in an upstream activating event absence. For instance, RasD is constitutively active as it does not bind the GTPase Activating Protein (GAP). Thus, it remains in the GTP-bound (active state) even when the cells are not triggered by growth factor to stimulate a receptor tyrosine kinase (RTK). Constitutively active Ras acts as cancer stimulating as the cells will flourish in the growth factors absence. Therefore, the standard regulatory mechanisms for cell proliferation are avoided.
(c)
To write:
The constitutive activation of (RasD) by a mutation in the Ras protein. The way in which activation of Ras promote cancer. The type of mutation that reduces the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB protein) proteins constitutively.
Introduction:
Constitutive activation is a phenomenon of the protein or signaling pathway modification. This modification is functional or involved in an upstream activating event absence. For instance, RasD is constitutively active as it does not bind the GTPase Activating Protein (GAP). Thus, it remains in the GTP-bound (active state) even when the cells are not triggered by growth factor to stimulate a receptor tyrosine kinase (RTK). Constitutively active Ras acts as cancer stimulating as the cells will flourish in the growth factors absence. Therefore, the standard regulatory mechanisms for cell proliferation are avoided.
Want to see the full answer?
Check out a sample textbook solution- What is the opening indicated by the pointer? (leaf x.s.) stomate guard cell lenticel intercellular space none of thesearrow_forwardIdentify the indicated tissue? (stem x.s.) parenchyma collenchyma sclerenchyma ○ xylem ○ phloem none of thesearrow_forwardWhere did this structure originate from? (Salix branch root) epidermis cortex endodermis pericycle vascular cylinderarrow_forward
- Identify the indicated tissue. (Tilia stem x.s.) parenchyma collenchyma sclerenchyma xylem phloem none of thesearrow_forwardIdentify the indicated structure. (Cucurbita stem l.s.) pit lenticel stomate tendril none of thesearrow_forwardIdentify the specific cell? (Zebrina leaf peel) vessel element sieve element companion cell tracheid guard cell subsidiary cell none of thesearrow_forward
- What type of cells flank the opening on either side? (leaf x.s.) vessel elements sieve elements companion cells tracheids guard cells none of thesearrow_forwardWhat specific cell is indicated. (Cucurbita stem I.s.) vessel element sieve element O companion cell tracheid guard cell none of thesearrow_forwardWhat specific cell is indicated? (Aristolochia stem x.s.) vessel element sieve element ○ companion cell O O O O O tracheid O guard cell none of thesearrow_forward
- Identify the tissue. parenchyma collenchyma sclerenchyma ○ xylem O phloem O none of thesearrow_forwardPlease answer q3arrow_forwardRespond to the following in a minimum of 175 words: How might CRISPR-Cas 9 be used in research or, eventually, therapeutically in patients? What are some potential ethical issues associated with using this technology? Do the advantages of using this technology outweigh the disadvantages (or vice versa)? Explain your position.arrow_forward
- Human Anatomy & Physiology (11th Edition)BiologyISBN:9780134580999Author:Elaine N. Marieb, Katja N. HoehnPublisher:PEARSONBiology 2eBiologyISBN:9781947172517Author:Matthew Douglas, Jung Choi, Mary Ann ClarkPublisher:OpenStaxAnatomy & PhysiologyBiologyISBN:9781259398629Author:McKinley, Michael P., O'loughlin, Valerie Dean, Bidle, Theresa StouterPublisher:Mcgraw Hill Education,
- Molecular Biology of the Cell (Sixth Edition)BiologyISBN:9780815344322Author:Bruce Alberts, Alexander D. Johnson, Julian Lewis, David Morgan, Martin Raff, Keith Roberts, Peter WalterPublisher:W. W. Norton & CompanyLaboratory Manual For Human Anatomy & PhysiologyBiologyISBN:9781260159363Author:Martin, Terry R., Prentice-craver, CynthiaPublisher:McGraw-Hill Publishing Co.Inquiry Into Life (16th Edition)BiologyISBN:9781260231700Author:Sylvia S. Mader, Michael WindelspechtPublisher:McGraw Hill Education